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Abstract
Background: Mast cells are hematopoietically derived cells that play a role in inflammatory processes such as allergy, as
well as in the immune response against pathogens by the selective and rapid release of preformed and lipid mediators,
and the delayed release of cytokines. The native homotetrameric lectin ArtinM, a D-mannose binding lectin purified from
Artocarpus heterophyllus seeds, is one of several lectins that are able to activate mast cells. Besides activating mast cells,
ArtinM has been shown to affect several biological responses, including immunomodulation and acceleration of wound
healing. Because of the potential pharmacological application of ArtinM, a recombinant ArtinM (rArtinM) was produced
in Escherichia coli. The current study evaluated the ability of rArtinM to induce mast cell degranulation and activation.
Results: The glycan binding specificity of rArtinM was similar to that of jArtinM. rArtinM, via its CRD, was able to
degranulate, releasing β-hexosaminidase and TNF-α, and to promote morphological changes on the mast cell surface.
Moreover, rArtinM induced the release of the newly-synthesized mediator, IL-4. rArtinM does not have a co-stimulatory
effect on the FcεRI degranulation via. The IgE-dependent mast cell activation triggered by rArtinM seems to be
dependent on NFkB activation.
Conclusions: The lectin rArtinM has the ability to activate and degranulate mast cells via their CRDs. The present study
indicates that rArtinM is a suitable substitute for the native form, jArtinM, and that rArtinM may serve as an important
and reliable pharmacological agent.
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Background
Mast cells are hematopoietically derived cells that reside
in the connective tissue [1–5] and play a major role in
the immune response in both physiological and patho-
logical processes such as allergy, inflammation, cardiac
disease, cancer, autoimmune diseases, and wound heal-
ing [6–9]. The activation of mast cells in these processes
results in degranulation, release of lipid mediators and
cytokines [10]. The mast cell mediators then recruit
other cell types including T lymphocytes, neutrophils,
and dendritic cells to inflammatory sites [11–13].
Lectins are among the diverse molecules that have
been shown to activate mast cells [14–16]. It has previ-
ously been shown that the native tetrameric ArtinM
(jArtinM), a D-mannose-binding lectin from Artocarpus
heterophyllus (jackfruit) seeds, induces the recruitment
of rat mast cells from bone marrow to the peritoneal cav-
ity [17], as well as inducing degranulation of rat peritoneal
mast cells [11]. In the rat mast cell line RBL-2H3, jArtinM
stimulates NFAT (nuclear factor of activated T-cells) and
NFkB (nuclear factor kappa-light-chain-enhancer of acti-
vated B cells) in an IgE independent manner [18]. In
addition to its action on mast cells, jArtinM also recruits
neutrophils [19] by binding to glycans of CXCR2 that
stimulate signal transduction via G protein [20], thus acti-
vating the cells and increasing their phagocytic activity
against pathogens [21]. jArtinM also has immunomodula-
tory activity. Systemic administration of jArtinM confers
protection against intracellular parasites such as
Leishmania major and Paracoccidioides brasiliensis,
by inducing IL-12 production through interaction
with TLR2 N-glycans, resulting in a Th1-type immune
response [22, 23].
A recombinant form of jArtinM, rArtinM, has been
heterologously expressed in Escherichia coli [24, 25].
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rArtinM is produced as soluble monomers with its
CRDs preserved and active [25]. Furthermore, the bind-
ing affinity of rArtinM to the trimannoside Manα1-3
[Manα1-6] Man from HRP, a N-glycosylated protein, is
similar to the native form [26]. Additionally, rArtinM
showed both prophylactic and therapeutic effects during
the course of P. brasiliensis infection in mice [27]. The
present investigation was undertaken to evaluate if rAr-
tinM, as a monomeric molecule, has the same ability as
jArtinM to activate mast cells. In the current study, rAr-
tinM was shown to have the same binding affinity to N-
glycans as the native form, jArtinM, and was also able to
activate and degranulate mast cells through its CRDs.
Results
Analysis of rArtinM
The objective of the present study was to characterize
the effect of monomeric rArtinM on mast cells. There-
fore, it was essential to confirm that rArtinM was indeed
monomeric. SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) was used to compare the homogeneity of
native and recombinant ArtinM preparations. Under
nondenaturing conditions or after thermal dissociation
rArtinM exhibited a single protein band of approxi-
mately 13 kDa that corresponds to rArtinM monomers
(Fig. 1a, lanes 1 and 2). jArtinM, the native tetrameric
form, was used as a control. When undenatured jArtinM
was loaded onto the gel, a protein band of approximately
60–80 kDa was observed. This band corresponds to jAr-
tinM tetramers (Fig. 1a, lane 3). When jArtinM was sub-
mitted to thermal dissociation, a single protein band of
approximately 13 kDa, corresponding to the dissociated
tetramers (Fig. 1a, lane 4), was observed. These results
indicate that E. coli expresses a monomeric form of
ArtinM. It is also plausible that E. coli expresses oligo-
meric forms of ArtinM but these forms cannot be
detected by electrophoresis, since their bonds could be
dissociated by exposure to SDS.
jArtinM and rArtinM were also submitted to size ex-
clusion chromatography on a Superdex 75 column,
which was calibrated by using protein molecular weight
standards. jArtinM presented two distinct peaks, the first
with the apparent molecular mass of 42 kDa and the
second peak with the apparent molecular mass of
22 kDa, together these two peaks had a molecular mass
of 64 kDa (Table 1). This estimate is compatible with
previous data from mass spectrometry analysis [28]. rAr-
tinM had the lowest molecular mass, 13 kDa, thus
reinforcing the hypothesis that rArtinM is expressed in a
monomeric form (Table 1).
Because both of these analytical techniques could re-
sult in the dissociation of weakly associated monomers,
Fig. 1 Analysis of rArtinM and jArtinM and analytical ultracentrifugation assay. a Lane 1: undenatured rArtinM. Lane 2: rArtinM after thermal dissociation.
Lane 3: undenatured jArtinM. Lane 4: jArtinM after thermal dissociation. 3 μg of protein were loaded to each lane. 12.5 % SDS-PAGE stained with
Coomassie blue G-250. b Size distribution obtained from the sedimentation velocity profiles of rArtinM at 20 °C. Fit and residuals after fitting to a c(S)
were calculated in SEDFIT. Plot of the distribution of sedimentation coefficients (C(s)) versus (S), where S is plotted in Svedberg units. The shape of the
major peak shows oligomeric structures of rArtinM. By non-linear fitting, the average molecular weight (Mw) for rArtinM was determined to be 50 kDa
(displayed inside the plot)
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an analytical ultracentrifugation assay (AUC) was per-
formed to determine if rArtinM monomers are able to
self-associate in solution. The AUC analysis, based on
the sedimentation velocity and also on the sedimentation
equilibrium, showed that in solution, rArtinM appeared
to be trimeric, and exhibited a molecular weight of ap-
proximately 50 kDa (Fig. 1b). Minor peaks were absent
from rArtinM. A previous AUC analysis of jArtinM
demonstrated that it has an S value of 4.24 and is a
64 kDa tetramer. However, jArtinM is capable of form-
ing higher order oligomeric species since there were
minor peaks at S values of approximately 6, 7, 9, 10 [29].
This is in agreement with previous results using molecu-
lar modeling [30]. To understand these differences, crys-
tal trials are being conducted on the two ArtinM forms
using the crystallization conditions published for native
artocarpin [30].
The molecular weights obtained from the sedimentation
velocities were confirmed by sedimentation equilibrium,
which makes no assumption regarding the hydrodynamic
shape of the protein. This analysis shows that, in solution,
rArtinM monomers are able to self-oligomerize, mostly
into trimers.
jArtinM and rArtinM share carbohydrate binding
specificity
It has been previously shown that rArtinM exhibits the
same binding affinity for the trimannoside Manα1-
3[Manα1-6] Man as does jArtinM. [25, 26] To assess the
carbohydrate-binding properties of jArtinM and rAr-
tinM at a higher resolution, glycan microarray analyses
was carried out using a panel of 255 lipid-linked oligo-
saccharide probes representing diverse mammalian gly-
can sequences and their analogs. Fifty N-glycan related
probes were included in the array. jArtinM (Fig. 2a) and
rArtinM (Fig. 2b) bound exclusively to the N-glycan se-
quences, in agreement with published data on the speci-
ficity of the native form [31]. There was no significant
difference in the specificities of the recombinant and na-
tive lectins, suggesting that the features that allow for
the modified oligomerization of rArtinM do not affect
the three-dimensional structure of its CRD, which is re-
sponsible for the glycan binding specificity.
rArtinM induces mast cell degranulation and activation
through its carbohydrate recognition domains (CRDs)
The next step was to investigate if the recombinant form
of ArtinM would be able to induce mast cell degranula-
tion. A dose–response curve for the release of β-
hexosaminidase and TNF-α was performed (Fig. 3). In
the absence of IgE, only the higher concentrations of
rArtinM were able to release β-hexosaminidase (20 and
40 μg/ml) and TNF-α (40 μg/ml) (Fig. 3a and b). On the
other hand, in the presence of IgE, all concentrations of
rArtinM induced β-hexosaminidase release (Fig. 3a), and
for TNF-α there was a greater release at 10 and 40 μg/
ml of rArtinM (Fig. 3b). The ability of rArtinM to induce
the production of the newly formed lipid mediator,
LTC4, was also examined. The production of LTC4 was
observed only in sensitized cells and occurred in a dose-
dependent manner (Fig. 3c). The synthesis of the newly-
synthesized mediator, IL-4, was also investigated. Only
the higher concentrations of rArtinM (20 and 40 μg/ml)
induced the synthesis and release of IL-4 either in the
presence or absence of IgE (Fig. 3d).
It was then of interest to determine if the degranulation
and activation induced by rArtinM was dependent on its
CRDs. Therefore, rArtinM (40 μg/ml) was pre-incubated
with its specific sugar, D-mannose, and β-hexosaminidase
release assay was performed. Pre-incubation of rArtinM
with D-mannose abolished the release of β- hexosamini-
dase, in the absence or presence of IgE (Fig. 4), indicating
that mast cell degranulation mediated by rArtinM is
dependent on its CRDs. The effect of rArtinM on mast
cell activation was also assessed by scanning electron mi-
croscopy (SEM). By SEM unstimulated RBL-2H3 cells are
spindle shaped and their surface is covered with fine
microvilli (Fig. 5). After stimulation via FcεRI the cells
have deep ruffles on their surface and are spread over the
substrate (Fig. 5). Incubation with rArtinM (40 μg/ml)
produced similar changes, which are consistent with mast
cell activation (Fig. 5). When rArtinM (40 μg/ml) was pre-
incubated with D-mannose, the cells had the same
morphological characteristics as the unstimulated cells
(Fig. 5). Taken together, these results show that mast cell
activation and degranulation induced by rArtinM is medi-
ated by its CRDs.
rArtinM does not have a co-stimulatory role in mast cell
degranulation via FcεRI
Since the recombinant form of ArtinM is produced as
monomers, it was of interest to investigate if rArtinM
could act as a co-stimulatory molecule in the FcεRI sig-
naling pathway. Co-stimulatory molecules act in parallel
with a major signaling pathway, either by amplifying the
intensity of the stimuli or by extending/prolonging its
time-response [32]. For this, rArtinM was incubated for
30 min along with the IgE-TNP specific antigen, DNP48-
Table 1 Estimate of the molecular weight by size exclusion gel
filtration chromatography
Sample Kav MW
jArtinM (peak 1) 0.1077 41.6584
JArtinM (peak 2) 0.2184 22.8336
rArtinM 0.3214 13.0524
jArtinM and rArtinM were submitted to size exclusion chromatography on a
Superdex 75 column. Eluted peaks were analyzed by retention volume and
molecular weight was calculated by its partition coefficient (Kav). 41.6 kDa
(jArtinM peak 1), 22.8 kDa (jArtinM peak 2), and 13 kDa (rArtinM)
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HSA, and β-hexosaminidase release assay was per-
formed. Interestingly, when rArtinM was jointly incu-
bated with DNP48-HSA, the levels of β-hexosaminidase
released were diminished by 37 % (Fig. 6) compared to
cells stimulated with DNP48-HSA alone, suggesting that
rArtinM disrupts the IgE-DNP48-HSA binding, probably
blocking the interaction between DNP48-HSA and IgE.
rArtinM activates the transcription factor NFkB
Since rArtinM was able to activate and degranulate mast
cells, it was of interest to investigate if rArtinM is
activating transcription factors such as NFkB and NFAT.
For this, transfected RBL-2H3 cell lines with a GFP-gene
reporter for NFkB and NFAT expression were used. rAr-
tinM was able to activate NFkB in an IgE-dependent
manner, but rArtinM did not activate NFAT (Fig. 7).
Discussion
The present study shows that the recombinant mono-
meric form of ArtinM, rArtinM, expressed in Escherichia
coli, has the ability to induce mast cell activation and de-
granulation. Activation by rArtinM resulted in the release
Fig. 2 Carbohydrate microarray analyses of jArtinM and rArtinM. Binding of jArtinM (a) and rArtinM (b) to a glycan array of 255 lipid-linked
oligosaccharide probes. Biotinylated ArtinM (50 μg/mL) was overlaid, and binding was detected after adding streptavidin conjugated to Alexa
Fluor 647. Glycoarray data analysis was performed with dedicated software. Numerical scores of the binding signals are means of duplicate spots
at 5 fmol/spot (with error bars). The various types of oligosaccharide linkage are indicated by the colored panels
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of preformed, newly formed, and newly-synthesized medi-
ators. Also, mast cell activation triggered by rArtinM re-
sults in morphological changes that are characteristic of
activated mast cells. Furthermore, mast cell activation in-
duced by rArtinM is dependent on its CRDs. Additionally,
the IgE-dependent activation of mast cells triggered by
rArtinM is dependent on NFkB activation.
The ubiquitous distribution of mast cells places them
in a privileged position to act as sentinel cells, respond-
ing rapidly to external signals by releasing their stored
preformed mediators and secreting newly-synthesized
lipid mediators [10]. One of the principal preformed me-
diators released during mast cell degranulation is TNF-α
[6, 33]. TNF-α is an important chemoattractant for
neutrophils and T cells during inflammatory processes
[11, 34–36]. Besides TNF-α, leukotrienes also play a role
in recruiting neutrophils and T cells to sites of inflam-
mation [7, 37]. The release of TNF-α and LTC4 induced
by rArtinM may help explain some of the biological
activities attributed to this lectin such as accelerated tis-
sue regeneration [38, 39] and amplified recruitment of
neutrophils [11].
It has been shown previously that monomers of rAr-
tinM share their primary structure with the native form
of ArtinM (jArtinM), which contributes to its correct
folding and exposure of its CRDs, leading to its proper
lectin-like activity [25]. This data supports our current
findings showing that the ability of rArtinM to activate
and degranulate mast cells is dependent on their CRDs.
The fact that rArtinM is expressed as monomers and
is able to oligomerize in solution, most likely because
of a high monomer concentration, supports our find-
ings, since mast cell activation and degranulation oc-
curred at high concentrations of rArtinM. A similar
dose-dependent effect was observed when rArtinM was
assayed for its effect on spleen cells. In spleen cells,
only high concentrations of rArtinM induced cell pro-
liferation and IL-2 production [40]. Although it shares
the sugar-binding specificity of jArtinM, rArtinM
differs in its avidity for glycotargets due to its unique
quaternary structure. The requirement for high concen-
trations of rArtinM in order to trigger cellular re-
sponses may be associated with its oligomerization
upon binding to glycoligands on the cell surface, as has
been well established for Galectin 3 [41]. Both IgE [42]
and FcεRI [43] are highly glycosylated. IgE contains sev-
eral mannose residues that could be targets for ArtinM
[44, 45]. FcεRI, also presents structural characteristics
that could favor its recognition by ArtinM such as sev-
eral N- glycosylation sites on the FcεRI α subunit [46].
Therefore, rArtinM may be activating mast cells by
cross-linking IgE or FcεRI.
Fig. 3 High doses of rArtinM are required for mast cell mediator release. a In the absence of IgE only 20 and 40 μg/ml of rArtinM induced β-
hexosaminidase release, and in the presence of IgE all doses induced β-hexosaminidase release. b In the absence of IgE only 40 μg/ml of rArtinM
stimulated release of TNF-α, whereas in IgE sensitized cells 10 and 40 μg/ml of rArtinM induced TNF-α release. c The release of LTC4 was seen
only in IgE sensitized cells. d rArtinM stimulation of IL-4 release did not require IgE. Data are expressed as mean ± SEM and are representative of
three separate experiments. *p < 0.05 or ** p < 0.01 or *** p < 0.001 between samples and the controls
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However, previous studies have demonstrated that
jArtinM is able to degranulate the rat mast cell line,
RBL-2H3, as well as peritoneal rat mast cells in an IgE-
independent manner [11, 18]. The possibility that
rArtinM interacts with other receptors on the mast cell
surface, such as TLR4 [6, 47], TLR2 [48, 49], the chemo-
kine receptor CXCR2 [50–52] and complement recep-
tors [7], should not be completely discounted, since
degranulation, IL-4 release and the morphological
changes on the mast cell surface triggered by rArtinM
all occurred in an IgE-independent manner.
It is well established that mast cells can respond in dif-
ferent manners to the same stimulus. For example, FcεRI
cross-linking results in NFkB activation leading to mast
cell degranulation [53]. However, exposure of IgE sensi-
tized mast cells to low concentrations of specific antigen
induces NFAT activation in the absence of degranulation
[54]. The same appears to be true for ArtinM. At 10 μg/
ml, jArtinM induces mast cell degranulation as well as
NFkB and NFAT activation [18], while rArtinM at the
same concentration does not induce degranulation. The
fact that rArtinM can activate mast cells in a pro-
inflammatory manner, without inducing degranulation,
makes it an attractive candidate for pharmacological use.
rArtinM was also able to induce IL-4 release. It is
known that IL-4 and another cytokines such as, IL-6,
VEGF, IL-13 and, TNF-α play a role in allergic inflam-
matory processes, leading to IgE production by B cells
[55, 56]. The ability of rArtinM to induce IL-4 release
agrees with our previous data showing that ArtinM can
trigger an allergic pro-inflammatory response [11, 18].
However, higher concentrations of rArtinM (20 and
40 μg/ml) were required to trigger responses similar to
those observed for jArtinM [18].
Conclusions
In the current investigation, monomeric rArtinM was able
to activate and stimulate mediator release by mast cells
through its CRDs. The mechanisms by which rArtinM
leads to mast cell activation is dependent on the transcrip-
tion factor NFkB, but not NFAT. These results demon-
strate that the mast cell response depends on the nature
and concentration of the stimuli. The present study indi-
cates that rArtinM is a suitable substitute for the native
form, since it shares some of the biological activities
already described for jArtinM. Therefore, rArtinM may
serve as an important and reliable pharmacological agent.
Methods
rArtinM preparations
rArtinM was expressed in Escherichia coli BL21- Codon-
Plus(DE3)-RP and purified as previously reported [25].
rArtinM preparations containing less than 0.05 ng/ml of
bacterial endotoxin, as determined by the Limulus amoe-
bocyte lysate assay, were used in this study (Sigma-Al-
drich., St. Louis, MO).
Size exclusion chromatography
Native and recombinant forms of ArtinM were submit-
ted to size exclusion chromatography for molecular
Fig. 4 rArtinM induces degranulation via its CRDs. When rArtinM (40 μg/ml) was preincubated with D-mannose for 1 h, β-hexosaminidase release
was abolished (black arrows). Data are expressed as mean ± SEM and are representative of three independent experiments. *** p < 0.001 between
samples and the controls
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weight determination, on a Superdex 75 column (Sigma
Aldrich) coupled to an AKTA protein purification system
(GE Healthcare, Uppsala, Sweden), which was calibrated
by using protein molecular weight standards (Protein
Mixture, GE Healthcare). The molecular weight of pro-
teins was determined by partition coefficient (Kav) using
this formula: Kav = Ve-Vo/Vt-Vo, where Ve is the elution
volume of the samples, Vt is the total volume and Vo is
the void volume of the gel bed. High molecular weight
blue dextran was used to determine the void volume.
Analytical ultracentrifugation
Sedimentation velocity measurements were performed
using a Beckman XL-A analytical centrifuge equipped
with both absorbance and interference optics. All data
were acquired at a rotor-speed of 50,000 rpm at 20 °C
using a Beckman An60Ti rotor. For each sample, 100
scans were acquired at 120 s intervals. Buffer density
and viscosity as well as the partial specific volume of the
protein were calculated using SEDNTERP (Alliance Pro-
tein Laboratories, Thousand Oaks, CA,).
Fig. 5 Activation induced by rArtinM occurs through a CRD-dependent manner. By scanning electron microscopy (SEM) deep ruffles are observed
on the surface of IgE sensitized mast cells after activation with DNP48-HSA and on the surface of rArtinM treated mast cells both in the absence
or presence of IgE. When rArtinM was preincubated with D-mannose, the cells are in spindle-shape and covered by fine microvilli on surface,
similar to unstimulated cells (Control). Bars = 10 μm
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Glycan array analysis
The native and recombinant ArtinM forms were biotinyl-
ated as previously described [38] and quantified by deter-
mining their absorbance at 280 nm (OD280). Microarrays
were composed of lipid-linked oligosaccharide probes ro-
botically printed in duplicate on nitrocellulose-coated
glass slides at 2 and 7 fmol per spot (in-house designation
sets 18–21bis) using a non-contact instrument, as previ-
ously described [57]. The microarray binding assays of
biotinylated ArtinM proteins were performed at 19 °C–
20 °C, as previously described [58]. In brief, the slide ar-
rays were blocked with 1 % w/v bovine serum albumin
(Sigma Aldrich) in casein blocking solution (Pierce Chem-
ical Co, Thermo Fisher, Waltham, MA) for 1 h. The bio-
tinylated ArtinM (50 μg/mL) was overlaid, and binding
was detected with streptavidin conjugated to Alexa Fluor
647 (Molecular Probes, Thermo Fisher, Waltham, MA) at
1 μg/mL in blocking solution. Glycoarray data analysis
was performed with dedicated software [59]. The binding
signals were probe-dose dependent.
Cells
RBL-2H3 cells, a rat mast cell line, were used in this study
[60]. The stable transgenic RBL-2H3 derived cell lines,
VB9 and NFkB 2, were also used. The VB9 cell line is a
GFP- reporter cell line for NFAT activation [54]. The
NFkB 2 cell line is a GFP-reporter cell line for NFkB acti-
vation [61], which presents a genome transduction with a
reporter vector that possess 4 copies of the binding site
for NFkB that regulate GFP expression. All cells were
grown as monolayers in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco, Thermo Fisher, Waltham, MA)
supplemented with 15 % fetal calf serum (Sigma-Aldrich)
as previously described [60]. Transfected cells were
Fig. 7 rArtinM activates NFkB, but not NFAT. rArtinM (40 μg/ml) induced NFkB activation only in the presence of IgE (a), but did not activate the
transcription factor NFAT either in the absence or in the presence of IgE (b). Data are expressed as mean ± SEM and are representative of three
separate experiments. *** p < 0.001 between samples and the controls
Fig. 6 rArtinM does not have co-stimulatory effect on mast cell degranulation via FcεRI. Cells sensitized with IgE and stimulated with the combination
of DNP48-HSA + rArtinM (40 μg/ml) had a decrease in β-hexosaminidase release. Data are expressed as mean ± SEM and are representative of three
separate experiments. ** p < 0.01 between samples and the controls
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selected with geneticin (0.4 mg/ml) (Sigma-Aldrich). All
cell lines were generously provided by Dr. Reuben P.
Siraganian, NIDCR, NIH, Bethesda, MD.
Cell sensitization and stimulation
As a positive control for FcεRI stimulated cells, the cells
were cultured in the presence of a 1:5000 dilution of
mouse IgE anti-TNP ascites fluid (kindly provided by
Dr. Reuben P. Siraganian) for 16 h, and then stimulated
with the multivalent specific antigen DNP48-HSA
(Sigma-Aldrich) at 50 ng/ml. As positive control for
FcεRI-independent stimulation, the cells were incubated
with calcium ionophore-A23187 (Sigma-Aldrich) at
0.1 μM for degranulation assays and, at 0.7 μM for NFkB
and NFAT activation assays. In experimental conditions,
the cells were sensitized or not with IgE anti-TNP asci-
tes fluid (1:5000) for 16 h and then stimulated with
rArtinM. In some experiments, rArtinM was preincu-
bated with D-mannose 100 mM (Sigma-Aldrich) for 1 h
at 4 °C. To evaluate release of preformed mediators (β-
hexosaminidase and TNF-α) and the lipid mediator
LTC4, cells were stimulated for 45 min. For scanning
electron microscopy, the cells were stimulated for
20 min. For newly-synthesized IL-4, the cells were stim-
ulated for 12 h. For NFkB and NFAT activation, the cells
were stimulated for 5 and 17 h respectively.
β-Hexosaminidase activity
3.0 × 104 cells/well were plated in 96 well tissue culture
plates (Corning Life Sciences, Lowell, MA) in the absence
or presence of IgE and cultured overnight. The cells were
washed 2 times with Tyrode’s buffer (137 mM NaCl;
2.7 mM KCl; 12 mM NaHCO3; 0.37 mM NaH2PO4;
0.1 mM MgCl2; 1.3 mM CaCl2; 10 mM Hepes, pH 7.3)
supplemented with 0.1 % BSA (Sigma-Aldrich) and 0.01 %
gelatin (Sigma-Aldrich) and then incubated with the
stimulus diluted in Tyrode’s buffer for 45 min as described
above in Cell sensitization and stimulation. After stimu-
lation, the supernatants were transferred to clean wells
and β-hexosaminidase activity measured as previously de-
scribed [1]. All assays were run in triplicate.
Leukotriene C4 and cytokine detection assays
IgE-sensitized or unsensitized cells were incubated with
rArtinM for 45 min or 12 h. The concentrations of
LTC4, TNF-α and IL-4 in the cell culture supernatants
were measured by ELISA (Leukotriene C4 EIA kit,
Cayman Chemical Company, MI, USA; OPTEIA™ Rat
TNF ELISA kit II; OPTEIA™ Rat IL-4 ELISA kit II, BD
Biosciences, San Jose, CA) according to the manufac-
turer’s instructions.
Scanning electron microscopy (SEM)
Cells (3x104) were cultured on 13 mm diameter glass
coverslips in 24 well plates (Corning Life Sciences). The
cells were cultured in the presence or absence of IgE for
16 h. The cells were then stimulated as described in Cell
sensitization and stimulation. The samples were pre-
pared as previously described [62], and were examined
with a JEOL JSM-6610 LV scanning electron microscope
(JEOL, Ltd.; Tokyo, Japan).
Flow cytometric measurements of NFkB and NFAT
activation
NFkB2 and VB9 cells (1x105) were sensitized or not with
IgE, and then stimulated. Fluorescence levels were mea-
sured using a Guava Personal Cell Analysis-96 System
and data were processed by Guava InCyte Software
(Millipore Co., Billerica, MA).
Statistics
Data was analyzed using GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA). Results were expressed as
mean ± SEM. Differences between groups were assessed
by one-way ANOVA followed by Tukey’s Multiple Com-
parison Test. *p < 0.05; **p < 0.01; ***p < 0.001.
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